Patents by Inventor Kasper Roet

Kasper Roet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11752200
    Abstract: Disclosed is a method for treating a subject having a neurological disorder characterized by the presence of toxic proteins comprising contacting the cerebrospinal fluid (CSF) of the subject with an agent capable of removing or degrading the toxic protein.
    Type: Grant
    Filed: January 20, 2021
    Date of Patent: September 12, 2023
    Assignee: EnClear Therapies Inc.
    Inventors: Manuel A. Navia, Kasper Roet, Jonathan Fleming
  • Publication number: 20230056486
    Abstract: Disclosed is a method for treating a subject having a neurological disorder characterized by the presence of dipeptide repeat proteins comprising contacting the cerebrospinal fluid (CSF) of the subject with an agent capable of removing or degrading the toxic protein.
    Type: Application
    Filed: July 28, 2022
    Publication date: February 23, 2023
    Inventors: Manuel A. Navia, Kasper Roet, Jonathan Fleming
  • Patent number: 11419921
    Abstract: Disclosed is a method for treating a subject having a neurological disorder characterized by the presence of dipeptide repeat proteins comprising contacting the cerebrospinal fluid (CSF) of the subject with an agent capable of removing or degrading the toxic protein.
    Type: Grant
    Filed: January 20, 2021
    Date of Patent: August 23, 2022
    Assignee: EnClear Therapies, Inc.
    Inventors: Manuel A. Navia, Kasper Roet, Jonathan Fleming
  • Publication number: 20220160947
    Abstract: Cerebrospinal fluid (CSF) and other fluid amelioration systems completely or partially implantable within a mammalian subject and associated methods include a substrate and an agent for amelioration of a toxic biomolecule present in the CSF or fluid, wherein the agent is disposed on or within the substrate.
    Type: Application
    Filed: February 11, 2022
    Publication date: May 26, 2022
    Inventors: Anthony DePasqua, Kevin Eggan, JR., Kevin Kalish, Manual A. Navia, Kasper Roet, Ching-Hua Tseng, Alan D. Watson, William X. Siopes, Gianna N. Riccardi, Marcie Ann Glicksman
  • Patent number: 11278657
    Abstract: Cerebrospinal fluid (CSF) and other fluid amelioration systems completely or partially implantable within a mammalian subject and associated methods include a substrate and an agent for amelioration of a toxic biomolecule present in the CSF or fluid, wherein the agent is disposed on or within the substrate.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: March 22, 2022
    Assignee: EnClear Therapies, Inc.
    Inventors: Anthony DePasqua, Kevin Eggan, Jr., Kevin Kalish, Manuel A. Navia, Kasper Roet, Ching-Hua Tseng, Alan D. Watson, William X. Siopes, Gianna N. Riccardi, Marcie Ann Glicksman
  • Publication number: 20210154276
    Abstract: Disclosed is a method for treating a subject having a neurological disorder characterized by the presence of dipeptide repeat proteins comprising contacting the cerebrospinal fluid (CSF) of the subject with an agent capable of removing or degrading the toxic protein.
    Type: Application
    Filed: January 20, 2021
    Publication date: May 27, 2021
    Inventors: Manuel A. Navia, Kasper Roet, Jonathan Fleming
  • Publication number: 20210145944
    Abstract: Disclosed is a method for treating a subject having a neurological disorder characterized by the presence of toxic proteins comprising contacting the cerebrospinal fluid (CSF) of the subject with an agent capable of removing or degrading the toxic protein.
    Type: Application
    Filed: January 20, 2021
    Publication date: May 20, 2021
    Inventors: Manuel A. Navia, Kasper Roet, Jonathan Fleming
  • Publication number: 20210023293
    Abstract: Cerebrospinal fluid (CSF) and other fluid amelioration systems completely or partially implantable within a mammalian subject and associated methods include a substrate and an agent for amelioration of a toxic biomolecule present in the CSF or fluid, wherein the agent is disposed on or within the substrate.
    Type: Application
    Filed: October 2, 2020
    Publication date: January 28, 2021
    Inventors: Anthony DePasqua, Kevin Eggan, JR., Kevin Kalish, Manuel A. Navia, Kasper Roet, Ching-Hua Tseng, Alan D. Watson, William X. Siopes, Gianna N. Riccardi, Marcie Ann Glicksman